PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

21st Congress of EHA

June 9th - June 12th 2016 Copenhagen

N. Poster

Poster title

Applicant name

Status


150-P	COMPARATIVE ANALYSIS OF GENE REGULATORY NETWORKS IN LYMPHOID LEUKEMIAS USING THE INTERACTIVE HEMAP RESOURCE	Juha Mehtonen	Received

152-P	HEDGEHOG PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PREDICTS RESPONSE TO SMO AND GLI1 INHIBITORS	Jolien De Bie	Received

153-P	IDENTIFICATION OF CANDIDATE ONCOGENES AND CHROMOSOMAL BREAKPOINT SEQUENCING BY TARGETED LOCUS AMPLIFICATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Eric Vroegindeweij	Received

154-P	A PLATFORM FOR DETECTION OF FUSION GENES IN ALL FROM TARGET CAPTURE NEXT-GENERATION SEQUENCING OF DNA AND RNA.	Andrea Grioni	Received

155-P	THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Marlies Vanden	Received

157-P	CHARACTERIZATION OF AN EX VIVO T-CELL CULTURE MODEL FOR THE STUDY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Simon Bornschein Bempt	Received

160-P	DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY.	Rajwinder Lehal Bempt	Received

162-P	LOSS OF PIGH EXPRESSION FREQUENTLY RESULTS IN A GPI-NEGATIVE SUBCLONE LACKING CD52 MEMBRANE EXPRESSION, CONFERRING ALEMTUZUMAB RESISTANCE TO B CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Inge JEDEMA	Received

164-P	BABOON ENVELOPE PSEUDOTYPED LENTIVIRAL VECTORS: A HIGHLY EFFICIENT NEW TOOL TO GENETICALLY MANIPULATE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA INITIATING CELLS	Melania TESIO	Received

165-P	HIGH INCIDENCE OF PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA (PH-LIKE ALL) IN OLDER ADULTS WITH B-ALL	Alexander Perl Bempt	Received

168-P	THE COMBINATION OF BORTEZOMIB AND CHEMOTHERAPY IS AN EFFECTIVE TREATMENT TO RE-INDUCE REMISSION IN RELAPSED/REFRACTORY B-CELL PRECURSOR OR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Alice BERTAINA Bempt	Received

169-P	EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB VERSUS 1ST- AND 2ND-GENERATION TYROSINE KINASE INHIBITORS FOR PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A META-ANALYSIS AND META-REGRESSION	Ariadne Souroutzidis Bempt	Received

170-P	RISK OF CEREBRAL VEIN THROMBOSIS (CVT) IN ADULT ALL PATIENTS IN FINLAND 1999-2012: SUGGESTION FOR A LEUKEMIA-RELATED PREDICTIVE SCORING MODEL	Saara Roininen	Received

171-P	INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA.	Nick MORLEY Bempt	Received

172-P	RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN OLDER/ELDERLY PATIENTS - A SWEDISH POPULATION-BASED STUDY	Emma BERGFELT Bempt	Received

173-LB		N. Toft	Received

174-P	VENTX INDUCES EXPANSION OF PRIMITIVE ERYTHROID CELLS AND CONTRIBUTES TO THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA IN MICE	Eva Gentner Bempt	Received

175-P	ABNORMAL INTRAGENIC TRANSCRIPTIONAL ACTIVATION IN MLL-AF9 AND KAT6A-CREBBP ACUTE MYELOID LEUKEMIA (AML)	Anna Marneth	Received

176-P	HHEX TRANSFORMS PROMYELOCYTES AND COOPERATES WITH FACTOR INDEPENDENCE TO CAUSE PROMYELOCYTIC LEUKEMIA IN MICE	Jacob T Jackson	Received

177-P	A SOMATIC MUTATION OF GFI1B IDENTIFIED IN LEUKEMIA ALTERS CELL FATE VIA A SPI1 (PU.1) CENTERED GENETIC REGULATORY NETWORK	Eduardo Anguita	Received

181-P	TRIB2 TRANSFORMED GMP AS THE MYELOID LEUKEMIA INITIATING CELL	Krishna Yalla Jackson	Received

182-P	TRIB2 REGULATES THE CELL CYCLE UNDER STRESS CONDITIONS IN A MURINE CELL MODEL OF LEUKEMIA.	Mara Salomè Bempt	Received

183-P	CHROMOTHRIPSIS: A NEW MECHANISM OF CANCER INITIATION AND PROGRESSION IN ADULT ACUTE MYELOID LEUKEMIA	Giovanni Martinelli Bempt	Received

184-P	AN EVALUATION OF THE TYROSINE KINASE INHIBITOR PACRITINIB IN PATIENTS WITH RELAPSED FLT3-MUTATED ACUTE MYELOID LEUKAEMIA (THE UK NCRI AML17 STUDY)	Steven Knapper Bempt	Received

186-P	SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDARUBICIN INDUCTION AND HIGH-DOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED FLT3+ AML	Meghan Macaraeg Bempt	Received

187-P	PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML.	Tapan Kadia	Received

188-P	DIFFERENTIATION RESPONSE TO GILTERITINIB (ASP2215) IN RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA PATIENTS IS ASSOCIATED WITH CO-MUTATIONS IN NPM1 AND DNMT3A	Jonathan Canaani Bempt	Received

190-P	CLINICAL RESPONSE IN RELAPSED/REFRACTORY AML PATIENTS CORRELATES WITH LEUKEMIC BLAST MOBILIZATION AND DIFFERENTIATION INDUCED BY BL-8040, A POTENT CXCR4 ANTAGONIST; RESULTS OF A PHASE IIA STUDY	Yaron Pereg	Received

193-P	A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES	Mark Frattini Bempt	Received

194-P	GENOMIC CHARACTERIZATION OF HIGH-COUNT MBL INDIVIDUALS INDICATES THAT EARLY DETECTION OF DRIVER MUTATIONS AND SUBCLONAL EXPANSION ARE PREDICTORS OF ADVERSE CLINICAL OUTCOME	Santiago Barrio	Received

195-P	IDENTIFICATION OF NOVEL B CELL RECEPTOR ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Elisa ten	Received

198-P	IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS OF CHRONIC LYMPHOCYTIC LEUKEMIA	Phuong-Hien Nguyen Hacken	Received

199-P	MICROENVIRONMENTAL STROMAL CELLS TRIGGER HYPOXIA SIGNALLING IN CLL CELLS – A MECHANISM THAT PROVIDES PROTECTION FROM APOPTOSIS AND CAN BE TARGETED THERAPEUTICALLY	Daniel Mertens	Received

200-P	IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS	Gabriela Pavlasova Hacken	Received

201-P	FUNCTIONAL IMPACT OF BONE MARROW MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES ON CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS: APOPTOSIS, MIGRATION, CHEMORESISTANCE AND GENE EXPRESSION MODIFICATION	Emerence Crompot	Received

202-P	THE T-CELL/CLL/MACROPHAGE TRIAD SHAPES A SUPPORTIVE TUMOR MICROENVIRONMENT IN CLL	Martijn van Attekum	Received

204-P	BLOCKING ENDOTHELIN-1 SIGNALING DISRUPTS LEUKEMIC CELL HOMING AND B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA	Rossana MAFFEI Attekum	Received

205-P	GENE EXPRESSION PROFILES OF PERIPHERAL BLOOD T AND NK-CELLS REVEALED DIFFERENT PATTERNS OF IMMUNE DYSFUNCTION IN CLL-LIKE MBL AND EARLY STAGE CLL	Anna Puiggros	Received

206-P	CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION	Erika Tissino Attekum	Received

210-P	PRELIMINARY RESULTS OF A PHASE II STUDY OF IBRUTINIB IN COMBINATION WITH FCR (IFCR) IN PREVIOUSLY UNTREATED, YOUNGER PATIENTS WITH CLL	Matthew Davids	Received

211-P	PRESENCE OF MULTIPLE UNMUTATED IGHV REARRANGEMENTS IN CLL PATIENTS IS ASSOCIATED WITH A VERY SHORT TREATMENT–FREE SURVIVAL: RESULTS FROM 2 INDEPENDENT COHORTS	Basile Stamatopoulos	Received

212-P	NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL	Marta Larrayoz Attekum	Received

213-P	UPDATED RESULTS OF A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IDELALISIB IN COMBINATION WITH OFATUMUMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Timothy Dichiara Attekum	Received

218-P	ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING FOR THE DETECTION OF SUBCLONAL TP53 ABERRATIONS IN CLL	Christian Brieghel Attekum	Received

219-P	COMPARABLE OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH REDUCED DOSE IBRUTINIB: RESULTS FROM A MULTI-CENTER STUDY	Rahul Banerjee Attekum	Received

221-P	PATIENTS WITH COMPLEX KARYOTYPE (CK) LACKING TP53 DELETIONS SHOW AN EQUIVALENT DISMAL CLINICAL OUTCOME AS THOSE WITH TP53 DELETIONS AND NON-CK IN CHRONIC LYMPHOCYTIC LEUKEMIA	Anna Puiggros Attekum	Received

230-P	IMPACT OF SECOND DECLINE RATE OF BCR-ABL1 TRANSCRIPT BETWEEN M3 AND M6 ON CLINICAL OUTCOME FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB: PRACTICAL ASPECT FOR THE TRUE LIFE	Stephanie DULUCQ Attekum	Received

232-P	LATE RELAPSES, UP TO 45 MONTHS AFTER IMATINIB DISCONTINUATION: RESULTS FROM THE ISAV STUDY	Silvia Mori Attekum	Received

233-P	ASSESSMENT OF THERAPY RESPONSE IN CHRONIC MYELOID LEUKEMIA VIA 1 MONTH BCR-ABL1 TRANSCRIPT DECLINE	Mohamed El Missiry	Received

234-P	DEVELOPMENT AND EVALUATION OF A MR1 – MR4.5 SECONDARY LYOPHILIZED CELL REFERENCE PANEL FOR BCR-ABL1 QUANTIFICATION ON THE INTERNATIONAL SCALE	Connie Wong Missiry	Received

235-P	TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS	Carmen FAVA	Received

236-P	MANAGING CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH HIGH-DOSE IMATINIB. THE ITALIAN EXPERIENCE.	Fiorina Giona Attekum	Received

238-P	VITAMIN C INCREASES VIRAL MIMICRY INDUCED BY 5-AZA-2-DEOXYCYTIDINE	Andreas Due Ørskov	Received

239-P	GENETIC PREDISPOSITIONS TO SPORADIC MYELOID NEOPLASMS CAUSED BY GERMLINE DDX41 MUTATIONS IN ASIAN AND CAUCASIAN POPULATIONS.	June Takeda Ørskov	Received

240-P	IDENTIFICATION OF ALTERED AND CRYPTIC-SPLICING IN SF3B1 MUTANT MYELODYSPLASTIC SYNDROMES AND ISOGENIC MODELS OF SF3B1-K700E MUTATION	Fabio Liberante	Received

241-P	IMPACT OF SOMATIC MUTATIONS ON OUTCOME IN PATIENTS WITH MDS AFTER STEM-CELL TRANSPLANTATION	Tetsuichi Yoshizato	Received

242-P	17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE	Roxana Schaab Ørskov	Received

243-P	TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS	M Teresa Cedena	Received

244-P	AZACYTIDINE RESTORES THE ABNORMAL STAT SIGNALING BIOSIGNATURE OF FOXP3+ T REGULATORY CELLS (TREGS) IN RESPONDING MDS PATIENTS.	Ioannis KOTSIANIDIS	Received

245-P	A CULTURE MODEL MIMICKING THE BM-NICHE ALLOWS FOR STUDYING THE DYSREGULATED ERYTHROPOIESIS OF SF3B1 MUTATED MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS	Edda María Elvarsdóttir	Received

246-P	THE INCIDENCE AND CLINICAL IMPLICATIONS OF CHROMOTHRIPSIS IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)	Zuzana Zemanova	Received

247-P	MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS.	Magnus Tobiasson Elvarsdóttir	Received

248-P	RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING EPOETIN ALFA VERSUS PLACEBO IN ANEMIC PATIENTS WITH IPSS LOW- INT1 RISK MDS	Wayne Elwood	Received

250-P	MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE	Lo-Ho Chen Elvarsdóttir	Received

252-P	CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q)	Guillermo Garcia-Manero Elvarsdóttir	Received

254-P	THE USE OF A HIGH DENSITY, 2.6 MILLION MARKER, SNP ARRAY AS THE PRIMARY GENETIC TEST FOR MYELODYSPLASTIC SYNDROME AT DIAGNOSIS: INTERIM FINDINGS OF THE WEST MIDLANDS, UK STUDY	Nicola Trim Elvarsdóttir	Received

257-P	FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA OF UNDETERMINED SIGNIFICANCE: ASSOCIATION WITH RISK OF PROGRESSION TO MYELODYSPLASTIC SYNDROME	Jakob Werner Hansen	Received

258-P	MOLECULAR AND CLINICAL TYPES OF PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH DISTINCT EXPRESSION PATTERNS OF LONG NONCODING RNAS	Martina Manzoni Hansen	Received

259-P	RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE	Isabel Hofman Hansen	Received

260-P	COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA WITH A DELETION OF CHROMOSOME 17P REVEALS A HIGH PREVALENCE OF SOMATIC TP53 MUTATIONS, WHICH CORRELATE WITH A POOR PROGNOSIS	Davine Hofste op	Received

261-P	DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY	Nicola GIULIANI	Received

262-P	LOSS OF PRIMING OR MCL-1 DEPENDENCY CONFERRED ACQUIRED RESISTANCE TO VENETOCLAX IN MULTIPLE MYELOMA	Martine Amiot op	Received

263-P	LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA	Ester Lozano op	Received

264-P	PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOWERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE ARREST	Sabrina Manni	Received

265-P	QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR IMPACT ON PATIENT SURVIVAL	Irena Misiewicz-Krzeminska op	Received

266-P	DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS	Kohichi Takada op	Received

267-P	DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR DIAGNOSTIC SERVICE	Piers Blombery	Received

276-P	THE SKY92 PROGNOSTIC MARKER IS VALIDATED IN EIGHT MULTIPLE MYELOMA CLINICAL DATASETS	Martin Van Vliet	Received

279-P	MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA STUDY	Marc Raab Vliet	Received

281-P	FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)	Eva Nordström	Received

282-P	PRECISION AS PART OF THE ANALYTICAL VALIDATION OF THE SKY92 HIGH RISK SIGNATURE AND THE MMPROFILER ASSAY	Martin Van Vliet	Received

283-P	RISK STRATIFICATION BY SKY92+ISS OUTPERFORMS IFISH MARKERS T(4;14) AND DEL(17P) IN MULTIPLE MYELOMA	Martin Van Vliet	Received

284-P	CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS	Dimitrios Christoulas Vliet	Received

285-P	LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT	Dimitrios Christoulas Vliet	Received

287-P	CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING SYNERGISTIC ACTIVITY IN MPN MODELS	Manjola Balliu Vliet	Received

290-P	LNK MUTATIONS IN FAMILIAL MYELOPROLIFERATIVE NEOPLASMS	Elisa Rumi	Received

291-P	HOMOZYGOUS CALRETICULIN MUTATIONS IN PATIENTS WITH MYELOFIBROSIS LEAD TO ACQUIRED MYELOPEROXIDASE DEFICIENCY	Alexandre THEOCHARIDES Vliet	Received

293-P	MESENCHYMAL STROMAL CELLS (MSC) FROM HIGH-GRADE BONE MARROW FIBROSIS PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (PH-NEG MPN) DISPLAY REDUCED CLONOGENICITY AND PROLIFERATION CAPACITY.	Benedetta RAMBALDI Vliet	Received

294-P	NEXT-GENERATION SEQUENCING IDENTIFIES MPL-TET2 MUTATED CLONES IN A SUBSET OF PATIENTS WITH JAK2V617F-POSITIVE MYELOFIBROSIS	Haifa Kathrin AL-ALI	Received

297-LB		Christian Pecquet	Received

298-P	CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST CELL DISEASE.	Carlos Fernandez	Received

299-P	MUTATIONAL STUDY OF GENES INVOLVED IN MYELOFIBROSIS BY MASSIVE SEQUENCING	Ana Africa Martin	Received

301-P	PREVENTION OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH HYDROXUYUREA PLUS PHLEBOTOMIES OR HYDROXYUREA ALONE	Alberto Alvarez-Larrán	Received

302-P	RATE OF MALIGNANT TRANSFORMATION IN HIGH RISK ET DURING 5 YEARS OF FOLLOW-UP OF CYTOREDUCTIVE THERAPY	Gunnar BIRGEGÅRD Martin	Received

304-LB		C. Harrison	Received

309-P	THE LYMPHOMA ASSOCIATED MACROPHAGES-HODGKIN/REED-STERNBERG CELLS RATIO IS A POOR PROGNOSTIC FACTOR IN CLASSIC HODGKIN LYMPHOMA PATIENTS	Vit Prochazka	Received

310-P	THE PROGNOSTIC ROLE OF BCL-2 EXPRESSION IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ASSESSED FOR CD68+ CELL COUNT.	Annarosa cuccaro Martin	Received

312-P	BIOLOGICALLY MEANINGFUL CHANGES IN CYTOKINE AND CHEMOKINE PRODUCTION FOLLOWING IBRUTINIB THERAPY IN WALDENSTROM´S MACROGLOBULINEMIA.	Josephine VOS Martin	Received

316-P	THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED / REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY	Constantine Tam Martin	Received

318-P	PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA	Dennis Healy Martin	Received

320-P	SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)	Caterina Cecchetti Martin	Received

322-P	TO SCREEN BIOLOGICAL MARKER GENE ASSOCIATED WITH B CELL IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) PATIENTS	Depei Wu Martin	Received

324-P	MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS	Mette Hazenberg Martin	Received

325-P	GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION INCREASES THE PROPORTION OF REGULATORY GAMMA DELT T CELLS	Qifa Liu	Received

326-P	PREACTIVATED MESENCHYMAL STROMAL CELLS IMPROVE T-CELL REGENERATION AFTER THEIR COTRANSPLANTATION WITH HEMATOPOIETIC STEM CELLS	Selim Kuci	Received

327-P	EVIDENCE OF COMPLEMENT DYSREGULATION IN TRANSPLANT – ASSOCIATED THROMBOTIC MICROANGIOPATHY	Eleni Gavriilaki	Received

328-P	FAMILY-DIRECTED CORD BLOOD BANKING FOR SICKLE CELL DISEASE: A 20-YEAR EXPERIENCE, ON BEHALF OF EUROCORD-MONACORD AND THE INTERNATIONAL SICKLE CELL DISEASE OBSERVATORY.	Hanadi Rafii Martin	Received

329-P	CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1 AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING	Aniko Szabo Martin	Received

330-P	RELAPSED/REFRACTORY HIGH GRADE B CELL NON-HODGKIN LYMPHOMA: SHOULD ONGOING PET POSITIVITY PRECLUDE AUTOLOGOUS TRANSPLANTATION IN PATIENTS ATTAINING A CT RESPONSE TO SALVAGE CHEMOTHERAPY?	Nagah Elmusharaf Martin	Received

331-P	MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Alex Ganetsky Martin	Received

332-P	HYPERACUTE GRAFT VERSUS HOST DISEASE: RISK FACTORS, OUTCOMES AND IMPACT OF TACROLIMUS/SIROLIMUS PROPHYLAXIS.	Oriana Lopez	Received

333-P	REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080)	Simon Rule	Received

334-P	THE ROLL OF HYPOMETHYLATING AGENTS IN MYELOID RELAPSES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT.	Félix López Cadenas	Received

335-P	IMPROVED CLINICAL OUTCOMES OF GBM/GPB MIXTURE HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO A PROPENSITY SCORE-MATCHED GPB HAPLOIDENTICAL TRANSPLANTATION: A MULTICENTER STUDY	Xiangyu zhao	Received

336-P	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION	Lotte VAN	Received

337-P	FIRST-LINE EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR ACUTE GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Andrea RIMONDO Godino	Received

338-P	EFFICACY OF HOST-DENDRITIC CELL VACCINATIONS WITH AND WITHOUT MINOR HISTOCOMPATIBILITY ANTIGEN LOADING, COMBINED WITH DONOR LYMPHOCYTE INFUSION IN MULTIPLE MYELOMA PATIENTS	Rimke Oostvogels DER	Received

339-P	TRACING OF URINARY EXCRETION OF BKV AND JCV BY QUANTITATIVE PCR IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (ALLO-HSCT) TO ANTICIPATE THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS (HC).	Joud Zanabili Al-Sibai	Received

340-P	OUTCOMES AFTER AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH MYC/BCL2 CO-EXPRESSION, DOUBLE-HIT LYMPHOMA, OR MYC COPY GAIN	Alex Herrera Al-Sibai	Received

341-P	BTLA GENOTYPE AND CLINICAL OUTCOME AFTER HLA-IDENTICAL SIBLING STEM CELL TRANSPLANTATION	Nazly Santos Al-Sibai	Received

342-P	HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN´S LYMPHOMAS (NHL)	Samer Srour Al-Sibai	Received

345-P	HIGH DOSE CHEMOTHERAPY WITH AUTOGRAFT MAY IMPROVE THE POOR PROGNOSIS OF NAIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH MYC/BCL2 CO-EXPRESSION	Francesco Maura Al-Sibai	Received

346-P	BIOMARKERS PREDICTING ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY IN 120 PATIENTS	Linda Cheyenne	Received

348-P	TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONOR IN PEDIATRIC SEVERE APLASTIC ANEMIA: EXPERIENCE WITH TCR ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING METHOD.	Daria SHASHELEVA Vaccari	Received

350-P	HHEX PROMOTES HSC SELF-RENEWAL AND STRESS HEMATOPOIESIS VIA REPRESSION OF CDKN2A	Jacob T Jackson	Received

352-P	NPM1 IS REQUIRED FOR NORMAL HEMATOPOIESIS	Chow Hiang Ang	Received

353-P	PLZF MUTATION ALTERS MOUSE HEMATOPOIETIC STEM CELL FUNCTION AND CELL CYCLE PROGRESSION	Christelle VINCENT-FABERT Ang	Received

354-P	IL-1 INDUCED ACTIVATION OF QUIESCENT HEMATOPOIETIC STEM CELLS IN VIVO	Uta Demel Vaccari	Received

356-P	CLEC-2 EXPRESSION IS A NEW MARKER FOR A SUBSET OF HEMATOPOIETIC STEM/PROGENITOR CELLS THAT CONTRIBUTES TO INFLAMMATION-INDUCED EMERGENT MEGAKARYOPOIESIS	Takahiro Kumode Vaccari	Received

357-P	IN VITRO AND IN VIVO STEM CELL PROPERTIES OF HIGHLY ENRICHED HUMAN BONE MARROW MESENCHYMAL STROMAL CELLS	Roshanak Ghazanfari	Received

358-P	GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS	Anindita Roy Vaccari	Received

359-P	GPR56: A NOVEL MOLECULE INVOLVED IN HEMATOPOIETIC STEM CELL GENERATION	Emma DE PATER	Received

364-P	CORD BLOOD DERIVED NK CELLS TRANSFER HISTONE H2AZ TO MULTIPLE MYELOMA CELLS CAUSING DIRECT AND INDIRECT CYTOTOXICITY	Beatriz Martín-Antonio PATER	Received

365-P	ALLOGENEIC TCRA/CD38 DOUBLE KNOCKOUT T-CELLS BEARING AN ANTI-CD38 CHIMERIC ANTIGEN RECEPTOR: AN IMPROVED IMMUNOTHERAPY FOR THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MULTIPLE MYELOMA.	Mathilde Dusseaux PATER	Received

366-P	OPTIMIZED AAV-MEDIATED HUMAN FACTOR VIII GENE THERAPY IN HEMOPHILIA A MICE AND CYNOMOLGUS MACAQUES	James Wilson PATER	Received

367-P	A DOSE-ESCALATING PRECLINICAL STUDY TO DETERMINE THE SAFETY, EFFICACY, AND MINIMUM EFFECTIVE DOSE OF A CLINICAL CANDIDATE VECTOR IN A MOUSE MODEL OF HEMOPHILIA B	James Wilson PATER	Received

368-P	THE LCR-FREE GAMMA-GLOBIN LENTIVIRAL VECTOR COMBINING TWO HPFH ACTIVATING ELEMENTS CORRECTS MURINE THALASSEMIC PHENOTYPE IN VIVO	Nicholas Anagnou	Received

369-P	BALANCE OF ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING AFFINITY AND DENSITY IN AN IN VITRO MODEL OF ACUTE MYELOID LEUKEMIA	Silvia Arcangeli	Received

370-P	PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS	Mira Patel PATER	Received

372-P	CEREBROVASCULAR RESERVE IN SICKLE CELL DISEASE ASSESSED WITH PERFUSION MAGNETIC RESONANCE IMAGING	Lena Vaclavu	Received

373-P	RESTING STATE FUNCTIONAL MRI SHOWS HOW COGNITIVE PERFORMANCES COULD BE PRESERVED IN CHILDREN WITH SICKLE CELL DISEASE	Raffaella Colombatti PATER	Received

377-P	ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND HOSPITAL ADMISSIONS FOR SICKLE CELL DISEASE: A RETROSPECTIVE TIME SERIES ANALYSIS	Sanjay Tewari PATER	Received

378-P	MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL OF INTRAVENOUS ITRACONAZOLE VS. LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR HEMATOLOGICAL MALIGNANCY WITH PERSISTENT FEVER AND NEUTROPENIA	Isao Yoshida PATER	Received

379-P	PREVALENCE, STRUCTURE, AND PUTATIVE MECHANISM FOR TEMPLATED INSERTIONS IN VDJ RECOMBINATION	Marvyn Koning PATER	Received

380-P	FLUOROQUINOLONE PROPHYLAXIS SIGNIFICANTLY AFFECTS BACTERIAL EPIDEMIOLOLOGY AND ANTIBIOTIC RESISTANCE BUT DOES NOT IMPACT ON INCIDENCE AND MORTALITY OF BLOODSTREAM INFECTIONS IN ACUTE LEUKAEMIA	Chiara CATTANEO PATER	Received

383-P	INVASIVE FUNGAL INFECTIONS IN LYMPHOPROLIFERATIVE DISORDERS: REVISION OF INCIDENCE IN THE "MODERN TREATMENT" ERA	Maria Chiara Tisi	Received

384-P	INFECTIOUS AND THROMBOTIC COMPLICATIONS IN PERIPHERALLY INSERTED (PICCS) COMPARED TO SHORT TERM CENTRAL VENOUS CATHETERS IN ONCOHEMATOLOGIC PATIENTS: A REL GROUP (RETE EMATOLOGICA LOMBARDA) STUDY	Nicola Stefano Fracchiolla	Received

385-P	USEFULNESS OF SERUM 1,3-B-D-GLUCAN FOR DIAGNOSIS OF INVASIVE FUNGAL DISEASE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS	Barbora Weinbergerova Fracchiolla	Received

386-P	DIFFERENT ISOFORM LOCALIZATION GOVERNS SIGNALING QUALITY OF DECTIN-1 IN THE REGULATION OF ANTI-FUNGAL IMMUNITY	Ulf Schnetzke Fracchiolla	Received

387-P	PRELIMINARY REPORT OF FUNGEMIA IN HEMATOLOGICAL MALIGNANCIES FROM SEIFEM-2015 SURVEY	Marianna Criscuolo Fracchiolla	Received

388-P	PROGNOSTIC FACTORS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT: EXPERIENCE WITH 335 PATIENTS FROM A SINGLE CENTER	Alfredo Rivas-Delgado Fracchiolla	Received

389-P	SAFETY AND EFFICACY OF HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) HYPERIMMUNE GLOBULIN AGAINST HTLV-1 INFECTION IN A HUMANIZED MOUSE MODEL.	Takuo Mizukami Fracchiolla	Received

391-P	AUDIT OF TRANSFUSION PRACTICES IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION AT UNIVERSITY HOSPITALS BIRMINGHAM	Aine BURKE Fracchiolla	Received

393-P	IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) USE ON TRANSFUSION REQUIREMENTS AND BLOOD LOSS IN CARDIAC SURGERY	Allison Mo Fracchiolla	Received

394-P	COMBINED PLASMA EXCHANGE AND ERYTHROCYTAPHERESIS FOR TREATMENT OF MULTIORGAN FAILURE DUE TO SUSPECTED FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE	Daniele Avenoso Fracchiolla	Received

396-P	EFFECTS OF IMPLEMENTATION OF A MASSIVE TRANSFUSION PROTOCOL IN A TERTIARY REFERRAL HOSPITAL	Ioannis Giannoutsos Fracchiolla	Received

397-P	LOW PREVALENCE OF ALLOIMMUNIZATION AFTER RED BLOOD CELL TRANSFUSION IN 182 CHILDREN WITH SICKLE CELL DISEASE.	Slimane Allali Fracchiolla	Received

402-P	NEW MUTATION C.-140C>G IN 5´UTR OF ANKRD26 GENE IN PATIENTS WITH MILD FORM OF INHERITED THROMBOCYTOPENIA ASSOCIATED WITH MALIGNANCIES.	Silvia FERRARI Fracchiolla	Received

403-P	MYCHOFENOLATE MOFETILE FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME. A RESTROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEAMATOLOGY/ONCOLOGY GROUP	Maurizio Miano Fracchiolla	Received

406-P	THE IMMUNOMODULATORY EFFECTS OF RETINIC ACID IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Qi Feng	Received

407-P	STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL AND MCL PATIENTS TREATED WITH IBRUTINIB - PRELIMINARY RESULTS	Darek Jawniak Vaccari	Received

408-P	CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA CASES IN THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (ADULT) REGISTRY	Indraraj Umesh Doobaree	Received

409-P	EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT	Sara Ali Doobaree	Received

410-P	ORAL DIRECT ANTICOAGULANTS IN THE TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION. RESULTS OF THE DAILY CLINICAL PRACTICE	Beatriz Perez Villardon	Received

411-P	SWITCH FROM VKA, LMWH OR FONDAPARINUX TO DOACS IN THE CLINICAL PRACTICE.	Francesco cortiula Villardon	Received

412-P	HIGH HEMOGLOBIN CONCENTRATIONS AND RISK OF THROMBOSIS: CAUSALITY OR CONFOUNDING?	Sæmundur Rögnvaldsson Villardon	Received

414-P	ANNEXIN A5 M2 HAPLOTYPE: TO BE OR NOT TO BE, THAT´S THE QUESTION!	Rita Tenreiro Villardon	Received

415-P	IRON METABOLISM IN PATIENTS WITH PORTAL THROMBOSES	Elena Lukina Villardon	Received

416-P	PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER-RELATED VENOUS THROMBOSIS IN PATIENTS WITH HEMATOLOGICAL DISEASES	Ana BOBAN Villardon	Received

417-P	EQUATIONS FOR ESTIMATING GFR: COMPARING RENAL FUNCTION CATEGORISATION IN THE CATCH STUDY	Mette Stagaard Janas	Received

418-P	A PROSPECTIVE EVALUATION OF THE IMPACT OF TRANSFUSION DEPENDENCY ON QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Francesco Sparano Janas	Received

422-P	PATIENT PREFERENCES, SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT, ASSOCIATED BURDEN AND SIDE EFFECTS	Carolin Buerkle	Received

423-P	UNDERESTIMATED IMPACT OF MILD COGNITIVE IMPAIRMENT IN "CLINICALLY FIT" OLDER PATIENTS WITH MALIGNANT HEMOPATHIES ADMITTED TO RECEIVE CHEMOTHERAPY	Dominique Bron Janas	Received

424-P	WHAT DO PATIENT EXPERIENCE DATA REVEAL ABOUT THE DIAGNOSTIC JOURNEY FOR MYELOMA PATIENTS? FINDINGS FROM SECONDARY ANALYSIS OF NATIONAL CANCER PATIENT SURVEY DATA	Sarah Richard Janas	Received

425-P	STREAMLINING OF THE CHEMOTHERAPY SERVICE WITH FOCUS ON DRUG SUPPLY AND PATIENT SAFETY	Heike Reinhardt Janas	Received

426-P	INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA	Ling-I HSU Janas	Received

526-P	IN VIVO ROLE OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) EXPRESSION IN THE DEVELOPMENT OF PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Franziska Auer	Received

528-P	THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA	Giovanni Cazzaniga Janas	Received

529-P	INSIGHTS INTO THE MOLECULAR EVOLUTION OF BCR-ABLP190 MEDIATED PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Franziska Auer Vaccari	Received

530-P	THE ROLE OF CNOT3 AND THE ENTIRE CCR4-NOT COMPLEX IN TUMOR DEVELOPMENT	Carmen VICENTE	Received

531-P	CAPTURE-BASED NEXT GENERATION SEQUENCING (NGS) IDENTIFIES ALSO RARE IG/TCR REARRANGEMENTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Marie Lorena	Received

532-P	MIR-126 DRIVEN LEUKEMIA: A MURINE MODEL TO UNDERSTAND HUMAN B-ALL PATHOGENESIS	Matteo Maria	Received

533-P	MUTATIONS IN TP53 AND JAK2 GENES ARE ASSOCIATED WITH POOR PROGNOSIS IN PEDIATRIC AND ADULT PATIENTS WITH B-CELL PRECURSOR ALL	Cristina Robledo	Received

536-P	TARGETING BET FAMILY PROTEINS IMPROVES THE THERAPEUTIC EFFICACY OF BCL-2 INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Sofie PEIRS NALDINI	Received

538-P	DELETIONS OF IKZF1 GENE, BUT NOT GENETIC RISK GROUPS, DEFINED BY COPY-NUMBER ALTERATIONS, ARE PROGNOSTICALLY SIGNIFICANT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ON ALL-MB 2008 PROTOCOL	Grigory TSAUR NALDINI	Received

539-P	LACK OF PROGNOSTIC SIGNIFICANCE OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE, B-CELL PRECURSOR ALL TREATED ACCORDING TO MRD-ORIENTED PROTOCOLS	Josep Maria	Received

541-P	PRELEUKEMIC CLONES IN NPM1-MUTATED AML MAY BE ASSOCIATED WITH EVOLUTION TO MYELODYSPLASTIC SYNDROME (MDS) OR MYELOPROLIFERATIVE NEOPLASM (MPN)	Sarah morin	Received

542-P	CLINICAL, HEMATOLOGICAL, BIOLOGIC AND MOLECULAR CHARACTERISTICS IN PATIENTS WHO DEVELOP ACUTE MYELOID LEUKEMIA FROM CHRONIC MYELOMONOCYTIC LEUKEMIA	Temeida Alendar Ribera	Received

544-P	SOMATIC DDX41 P.R525H MUTATION CAUSES GROWTH DEFECT IN HEMATOPOIETIC CELLS	Hirotaka Matsui	Received

545-P	WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN FAMILIAL MDS/AML	Ana Rio-Machin Ribera	Received

547-P	POOR PROGNOSIS MONOSOMIC AND TRISOMIC ACUTE MYELOID LEUKEMIA ASSOCIATES WITH CHECKPOINTS AND CDC20 DEREGULATION: A NOVEL LEUKEMOGENIC MECHANISM AND THERAPEUTIC TARGETS	Giorgia Simonetti Ribera	Received

549-P	PHYSIOPATHOLOGICAL MECHANISM OF LEUKEMIC PREDISPOSITION IN ANKRD26-RD PATIENTS	Alessandro Donada	Received

550-P	NOTCH SIGNALLING INHIBITION AS A MULTI-TARGET THERAPY TO OVERCOME BONE MARROW MICROENVIRONMENT-MEDIATED DRUG RESISTANCE IN AML	Paul Takam Kamga	Received

552-P	ENANTIOMER-SPECIFIC AND PARACRINE LEUKEMOGENICITY OF MUTANT IDH METABOLITE 2-HYDROXYGLUTARATE	Anuhar Chaturvedi	Received

553-P	INVOLVEMENT OF THE TRANSCRIPTION FACTOR ASCL2 IN NORMAL AND LEUKEMIC HEMATOPOIESIS	Mallorie Dépond Kamga	Received

555-P	IN VIVO SHRNA SCREEN IDENTIFIES SPLICING FACTOR RBM25 AS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA	Ying Ge	Received

556-P	HIGH MTORC1 ACTIVITY DRIVES GLUCOSE METABOLISM ADDICTION AND SENSITIVITY TO G6PD INHIBITION IN ACUTE MYELOID LEUKEMIA CELLS	Laury Poulain	Received

559-P	IDENTIFICATION OF A NOVEL STAT5 INHIBITOR TO INTERFERE WITH THE ONCOGENIC ACTIVITIES OF STAT5 IN AML	Bettina Wingelhofer	Received

561-P	DOUBLE INACTIVATION OF TET2 AND TET3 INDUCES HYPOMETHYLATING AGENT-SENSITIVE ACUTE MYELOID LEUKEMIA	Koichiro Maie Kamga	Received

562-P	NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE.	Lynn Quek Kamga	Received

563-P	HIGH PREDICTIVE VALUE OF COMBINED WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA	Fabio Guolo	Received

565-P	DNMT3A AND IDH1 MUTATIONS WORSEN THE PROGNOSIS OF ELN GOOD RISK (CEBPA OR NPM1 MUTATED/FLT3 UNMUTATED) AML PATIENTS	Jana Marková Ribera	Received

567-P	NANOG EXPRESSION AS A RESPONSIVE BIOMARKER DURING TREATMENT WITH HEDGEHOG SIGNAL INHIBITOR IN ACUTE MYELOID LEUKEMIA	Seiji Kakiuchi	Received

569-P	AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO FIRST LINE ACUTE MYELOID LEUKEMIA TREATMENT	Ana Espinosa	Received

570-P	RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA	Shaun Fleming Kamga	Received

571-P	CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+ AML) PATIENTS WITH INCREASED RISK OF RELAPSE.	Anna Porwit	Received

575-P	THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Giovanni Martinelli	Received

577-P	PHARMACEUTICAL TARGETING OF PYRUVATE DEHYDROGENASE KINASES IN T(8;21) ACUTE MYELOID LEUKEMIA	Hüsün Kizilkaya Kamga	Received

578-P	HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS	Chien-Chin Lin	Received

580-P	LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL)	Sameer A. Parikh	Received

580-LB		Mohamed Sorror	Received

581-P	COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q DELETION	Sara Raponi	Received

586-P	IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPROLIFERATIVE DISORDERS	Andy Rawstron Parikh	Received

587-P	REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE	Ilaria Del Giudice	Received

588-P	PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS	Zuzana Jaskova Giudice	Received

589-P	PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT	Andy Rawstron	Received

590-P	THE SYK\JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA	Andrew STEELE	Received

592-P	IBRUTINIB FOR RELAPSED CLL PATIENTS OLDER THAN 75 YEARS: PROVEN EFFICACY, TOXICITIES TO KNOW	Anne-Sophie MICHALLET Giudice	Received

595-P	CHROMOSOME 8 ABNORMALITIES ARE ASSOCIATED WITH AN EVEN WORSE OUTCOME AND KARYOTYPE COMPLEXITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND TP53 ABERRATIONS	Gonzalo Blanco	Received

598-P	NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2	Panagiotis Baliakas Giudice	Received

601-P	ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML	Stefania Rocca	Received

602-P	A NOVEL C-TERMINAL HSP90 INHIBITOR WITH THERAPEUTIC EFFECT IN IMATINIB RESISTANT CML.	Sanil Bhatia Ribera	Received

604-P	MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA	Ilaria Stefania Pagani	Received

605-P	CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA	Dimitrios Karamitros Pagani	Received

606-P	ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS	Manuela Mancini Pagani	Received

610-P	THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA	Lucy Fox Pagani	Received

611-P	THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA	Sara Galimberti Pagani	Received

612-P	REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML	Mario Tiribelli Pagani	Received

613-P	FACTORS THAT INFLUENCE PATIENT WILLINGNESS TO ATTEMPT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA	David Ross Pagani	Received

614-P	GENETIC VARIABILITY OF OXIDATIVE STRESS AND DNA REPAIR GENES – POTENTIAL PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN CHRONIC MYELOID LEUKEMIA	Ana Cristina Gonçalves	Received

616-P	BCR-ABL1 TRANSCRIPT LEVEL ON DAY+28 CAN PREDICT EARLY MOLECULAR RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO TREATED WITH FRONTLINE DASATINIB	Won Sik LEE	Received

619-P	IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA	Alessandra Freyrie Gonçalves	Received

620-P	AGE DISTRIBUTION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN GERMANY AND THEIR PROGNOSIS ACCORDING TO THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS): DATA FROM THE REGULAR CARE MDS REGISTRY	H Tilman Steinmetz	Received

621-P	VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER	Daniel Moreno Berggren	Received

622-P	EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH OR WITHOUT EVOLUTION TO LEUKEMIA	Yan MA Berggren	Received

623-P	HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY.	Bastida Jose Maria	Received

625-P	CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014	Avinash Dinmohamed Maria	Received

626-P	LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES	Amy DeZern Maria	Received

627-P	THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION OF PATIENTS WITH LOWER-RISK MDS.	Teresa Knight Asorey	Received

628-P	STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION	Nataliya PETINATI	Received

629-P	SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY?	Eva-Stina Kairemo Asorey	Received

632-P	A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495, A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Jeffrey Johnston Asorey	Received

633-P	THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC ANEMIA (AA) PATIENTS.	Thomas Nevill Asorey	Received

638-P	IKAROS PROTEIN EXPRESSION IN BONE MARROW B AND T CELLS RATHER THAN MYELOMA CELLS PREDICTS OUTCOME AFTER LENALIDOMIDE-DEXAMETHASONE THERAPY	Arnold Bolomsky Asorey	Received

639-P	CXCL13 CHEMOKINE – A NOVEL TARGET IN MULTIPLE MYELOMA MICROENVIRONMENT	Katia BEIDER Asorey	Received

640-P	MESENCHYMAL STEM CELLS (MSC) PROMOTES TUMOR MICROENVIRONMENT TRANSFORMATION DRIVING GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ACTIVATION IN SMOLDERING AND MULTIPLE MYELOMA PATIENTS	Daniele Tibullo Asorey	Received

641-P	TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH & SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT	Arnold Bolomsky Asorey	Received

642-P	LENALIDOMIDE MAINTENANCE COUNTERACTS PD-1 ELEVATION ON LYMPHOCYTES IN MYELOMA PATIENTS	Sophia Danhof Maria	Received

643-P	CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS	Fedor Kryukov	Received

644-P	PRECLINICAL EVALUATION OF ABBV-838, A FIRST-IN-CLASS ANTI-CS1 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF MULTIPLE MYELOMA	Kurt Gish Asorey	Received

648-P	PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA	Tyce Havens	Received

650-P	OUTCOME OF MYELOMA PATIENTS WITH DELETION 17P – IMPACT OF BASELINE CHARACTERISTICS, TREATMENT AND ADDITIONAL CHROMOSOMAL CHANGES	Maximilian Merz	Received

651-P	CIRCULATING TUMOR DNA IN MULTIPLE MYELOMA	Even Holth Rustad	Received

654-P	PROSPECTIVE COMORBIDITY AND FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA) IN MULTIPLE MYELOMA (MM) PATIENTS (PTS): RESULTS FROM A MULTICENTER GERMAN STUDY GROUP MM (DSMM) TRIAL	Sandra Dold Rustad	Received

657-P	PROSPECTIVE EVALUATION OF GERIATRIC ASSESSMENT TOOLS IN REAL-WORLD, UNSELECTED, ELDERLY PATIENTS WITH SYMPTOMATIC MYELOMA	Efstathios Kastritis	Received

665-P	PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND STANDARD-RISK CYTOGENETICS	Moritz Binder	Received

666-P	CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE	Georgia METZGEROTH Rustad	Received

667-P	THROMBOTIC RISK IN IDIOPATHIC ERYTHROCYTOSIS IS LOWER THAN IN POLYCYTHEMIA VERA BUT HIGHER THAN IN GENERAL POPULATION.	Maria Luigia Randi	Received

669-P	COMPARISON OF GENOMIC DNA-BASED VS. MESSENGER RNA-BASED KIT D816V MUTATION ANALYSIS REVEALS LARGE DIFFERENCES BETWEEN BLOOD AND BONE MARROW IN SYSTEMIC MASTOCYTOSIS	Thomas Kristensen Randi	Received

670-P	3167 NEWLY DIAGNOSED MPN PATIENTS, A REPORT FROM THE SWEDISH MPN REGISTRY	Björn Andreasson Randi	Received

671-P	PREDICTIVE ROLE OF CIRCULATING LEUCOCYTE-PLATELET AGGREGATES FOR THROMBOEMBOLIC COMPLICATIONS IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A PROSPECTIVE STUDY	Dijana Šefer	Received

672-P	PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS	Nicola Polverelli	Received

676-P	PROGNOSTIC IMPACT OF INTEGRATED GENOMIC PROFILING IN ADULT T-CELL LEUKEMIA/LYMPHOMA	Keisuke Kataoka	Received

677-P	HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET	Miguel Gallardo Randi	Received

678-P	GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE.	Shamzah Araf Randi	Received

679-P	SOMATIC MUTATION PROFILING FOR PROGNOSIS AND TREATMENT STRATIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE REMODL-B TRIAL	Ming Qing Du	Received

680-P	ADHESION MOLECULE JAM-C: A POTENTIAL TARGET FOR MANTLE CELL LYMPHOMA THERAPEUTICS	Thomas Matthes Randi	Received

681-P	ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL LYMPHOMA BUT DO NOT IMPACT PATIENTS´ SURVIVAL	Andrea MARECKOVÁ Randi	Received

683-P	TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONE ITALIANA LINFOMI (FIL)	Simone Ferrero	Received

684-P	DECIPHERING THE IMPACT OF IDELALISIB ON FOLLICULAR LYMPHOMA AND ITS IMMUNE MICROENVIRONMENT	Patricia Pérez-Galán Randi	Received

685-P	MIR-34A PREVENTS LUNG INJURY IN BLEOMYCIN INDUCED PULMONARY FIBROSIS	Raanan Bulvik Du	Received

686-P	INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA	Rumiko Kanzaki Randi	Received

687-P	PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL	Laura Magnano Randi	Received

688-P	DISTINCT INCREASING TREND AND BIRTH-COHORT EFFECT OF FOLLICULAR LYMPHOMA INCIDENCE IN TAIWAN: EPIDEMIOLOGICAL ANALYSES AND IMPLICATIONS	Shang-Ju Wu	Received

689-P	LONG-TERM OUTCOMES OF 131I-RITUXIMAB RADIOIMMUNOTHERAPY IN FOLLICULAR NON-HODGKIN LYMPHOMA: TEN YEAR UPDATE ON TOXICITY, TIME-TO-NEXT-TREATMENT AND SURVIVIAL OF THE PHASE II INITIAL STUDY	Murali Kesavan	Received

690-P	LONG TERM OUTCOMES IN PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS (POAML): A LARGE SINGLE INSTITUTE COHORT STUDY.	Amrita Desai	Received

691-P	EARLY TRANSFORMATION IN LOW-GRADE LYMPHOMAS AND ITS ADVERSE PROGNOSTIC SIGNIFICANCE ON SURVIVAL	Luis Miguel Juárez	Received

692-P	OFATUMOMAB FOR THE TREATMENT OF EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA): THE O-MA1 STUDY	Barbara Kiesewetter	Received

694-P	FINAL RESULTS OF IHC ANALYSIS AND PROGNOSTIC FACTORS IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION	Manali Kamdar Juárez	Received

695-P	IMPROVED OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH PRESERVATION OF COGNITIVE FUNCTION	Shireen Kassam Juárez	Received

697-P	NONPEGHYLATED LIPOSOMAL DOXORUBICIN AS A COMPONENT OF R-CHOP IS EFFECTIVE AND SAFE IN THE TREATMENT OF A CARDIAC HIGH-RISK AND ELDERLY LYMPHOMA PATIENTS	Luigi Rigacci Juárez	Received

698-P	METHYLATION OF CELL-FREE CIRCULATING DNA IN PLASMA PREDICTS POOR OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA	Lasse Sommer	Received

701-P	DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: REAL LIFE ANALYSIS OF PATIENTS WITH REFRACTORY DISEASE OR RELAPSE	Bente Arboe Kristensen	Received

702-P	CENTRAL NERVOUS SYSTEM INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL LYMPHOMA	Naoto Tomita Kristensen	Received

704-P	DETECTION OF BONE MARROW INVOLVEMENT OF DLBCL - COMPARISON OF PET-CT AND BONE MARROW BIOPSY	Yuki Nakajima	Received

707-P	A NOVEL QUANTITATIVE PCR APPROACH TARGETING INSERTION/DELETION POLYMORPHISMS (INDEL-PCR) FOR CHIMERISM QUANTIFICATION: FINALLY HIGH SENSITIVITY AND QUANTIFICATION CAPACITY TOGETHER	Almudena Navarro-Bailón Kristensen	Received

708-P	A NEW APPROACH OF DUAL-SCT WITH UNMANIPULATED HAPLO-IDENTICAL GRAFT AND UNRELATED CORD BLOOD IN PATIENTS WITH HEMATOLOGICAL DISORDERS	Depei Wu Kristensen	Received

709-P	RECIPIENT CCR5 GENETIC VARIATION PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED DONOR BONE MARROW TRANSPLANTATION.	Tomohiro Horio Kristensen	Received

710-P	PRESUMABLY FALSE POSITIVE MINIMAL RESIDUAL DISEASE (MRD) QPCR RESULTS AFTER ALLOGENEIC SCT UNCOVERED BY NEXT GENERATION SEQUENCING (NGS)	Michaela Kotrová Kristensen	Received

711-P	PRE-EMPTIVE THERAPY WITH IFN-?-2B FOR ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT	Depei Wu Kristensen	Received

712-P	A STUDY OF RHTPO IN COMBINATION WITH CHEMOTHERAPY AND G-CSF FOR PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA	Haitao Bai Kristensen	Received

713-P	A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION	Inge JEDEMA Kristensen	Received

714-P	WHICH CONDITIONING REGIMEN IS MORE EFFECTIVE FOR HIGH-RISK PATIENTS WITH AML/MDS : COMPARING LOW-DOSE DECITABINE COMBINED WITH MODIFIED BUCY WITH MODIFIED BUCY FOLLOWED BY ALLO-HSCT	Depei Wu Kristensen	Received

715-P	ELEVATED EXPRESSION OF TIM-3 ON CD8 T CELLS CORRELATES WITH CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENIC STEM CELL TRANSPLANTATION	Depei Wu Kristensen	Received

716-P	INTERFERON-GAMMA GENE POLYMORPHISM ASSOCIATE WITH MORTALITY AND GRAFT-VERSUS-HOST DISEASE SEVERITY IN HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION	Maria Virginia	Received

718-P	BASELINE LABORATORY VARIABLES SERVE AS POTENT PREDICTORS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RELATED MORTALITY	Roni SHOUVAL	Received

720-P	COMPARING TIME-DEPENDENT PREDICTIVE PERFORMANCE OF ALLOGENEIC HSCT RISK SCORING SYSTEMS	Joshua Fein Palau	Received

721-P	PROPHYLACTIC DLI VS NO DLI FOR REFRACTORY ACUTE LEUKEMIA UNDERGOING ALLO-HSCT WITH SEQUENTIAL INTENSIFIED CONDITIONING	Qifa Liu Palau	Received

722-P	THE PRE-TRANSPLANT BIOMARKER RISK INDEX BASED ON SERUM FERRITIN, ALBUMIN AND CRP CAN PREDICT OUTCOMES INDEPENDENTLY OF THE HCT-CI AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Tatsuya Suwabe Palau	Received

723-P	HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA	Shuning Zuo Palau	Received

725-P	MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE GUIDED SEQUENTIAL CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION COULD IMPROVE SURVIVAL OF PATIENTS WITH ACUTE LEUKEMIA WHO RELAPSED AFTER ALLO-HSCT	Chen Hua Yan	Received

727-P	BIFURCATION INTO HEMATOPOIETIC STEM CELL TYPES IS DEPENDENT UPON THE DEVELOPMENTAL SIGNALING MOLECULES	Mihaela CRISAN Palau	Received

728-P	LACK OF MIR-127 DOWN-REGULATION IN THE TRANSITION FROM HEMATOPOIETIC STEM CELLS TO MULTI-POTENT PROGENITORS LEADS TO PANCYTOPENIA AND DEFECTIVE SELF-RENEWAL	Francesca Ficara Palau	Received

729-P	NAMPT-NAD+-SIRT2 PATHWAY-TRIGGERED DEACETYLATION OF LMO2 PROTEIN IS INDISPENSABLE IN THE EARLY HEMATOPOIESIS THROUGH COMPLETE TAL1 COMPLEX FORMATION	Tatsuya Morishima	Received

731-P	EXPRESSION OF BCL2, BUT NOT STAT5 SIGNALING, RESCUES LYMPHOPOIESIS IN THE ABSENCE OF HHEX	Jacob T	Received

732-P	ANAMORSIN IS ESSENTIAL FOR B-CELL TERMINAL DIFFERENTIATION	Yuri Hamanaka	Received

733-P	DOWNREGULATION OF CD44 FUNCTIONALLY DEFINES HUMAN T-CELL COMMITMENT	Kirsten Canté-Barrett	Received

734-P	KNOCKDOWN OF THE ADHESION G-PROTEIN COUPLED RECEPTOR 56 IMPAIRS HUMAN CORD BLOOD STEM AND PROGENITOR CELL FUNCTION	Lixiazi He Palau	Received

735-P	DISSECTING THE ROLE OF THE MICROENVIRONMENT IN APLASTIC ANEMIA USING AN IN VIVO HAEMATOPOIETIC STEM CELL NICHE MODEL	Ilaria Marina Michelozzi	Received

737-P	EFFICIENT GENOME EDITING OF MOUSE HEMATOPOIETIC CELLS USING CRISPR/CAS9 TECHNOLOGY	Evgenia Sarrou	Received

738-P	COMPREHENSIVE PROTEOMIC ANALYSIS OF HUMAN ERYTHROPOIESIS	Emilie-Fleur GAUTIER	Received

740-P	STAPHYLOCOCCUS AUREUS PROTEIN ISDH INHIBITS THE CD163 PATHWAY FOR HAPTOGLOBIN-FACILITATED HEMOGLOBIN SCAVENGING	Kirstine Lindhardt Madsen	Received

742-P	AG-519 IS A POTENT ACTIVATOR OF MUTANT PYRUVATE KINASE ASSOCIATED WITH HEMOLYTIC ANEMIA	Charles Kung Madsen	Received

743-P	REDPLEX: A TARGETED NEXT GENERATION SEQUENCING-BASED DIAGNOSIS FOR PATIENTS WITH HEREDITARY HEMOLYTIC ANEMIAS	Roberta Russo Madsen	Received

745-P	ELEVATED PLASMA ASYMMETRIC DIMETHYLARGININE LEVELS IN CHILDREN WITH BETA-THALASSEMIA MAJOR MAY BE AN EARLY MARKER FOR ENDOTHELIAL DYSFUNCTION	Orhan GURSEL Madsen	Received

747-P	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING PRACTICE FROM UK CENTRES: A REPORT FROM THE UK PNH NETWORK	Morag griffin Michelozzi	Received

748-P	DIAGNOSTIC VALUES FOR IRON DEFICIENCY ANEMIA IN CHILDREN AND WOMEN USING SERUM HEPCIDIN AND ZINC PROTOPORPHYRIN (ZPP)	Giridhar Kanuri Madsen	Received

749-P	UTILITY OF RED CELL INDICES TO DIAGNOSE IRON DEFICIENCY IN RURAL INDIAN CHILDREN	Swaratika majumdar Madsen	Received

751-P	SEARCH AND YOU SHALL FIND – VARIANT HEMOCHROMATOSIS GENE MUTATIONS AS A CAUSE OF HYPERFERRITINEMIA IN BLOOD DONORS	Adam Høgsbro	Received

752-P	A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG-519, AN ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R IN HEALTHY SUBJECTS	Ann Barbier	Received

753-P	ANALYSIS OF MOLECULAR MECHANISMS OF DOMINANT-INTERFERING FAS MUTATIONS	Daniel Schäfer Laursen	Received

754-P	UNSMAKING PRIMARY IMMUNE DEFICIENCIES IN EARLY-ONSET EVANS SYNDROME USING IMMUNOPHENOTYPING AND NGS: TOWARDS A CLINICAL AND GENETIC CLASSIFICATION	Nathalie Aladjidi Laursen	Received

755-P	MRI SKELETAL MANIFESTATIONS IN GAUCHER DISEASE: UTILITY OF SPANISH-MRI (S-MRI) SCORE AT DIAGNOSIS AND FOLLOW-UP	Marcio Andrade-Campos Laursen	Received

756-P	SEVUPARIN DEMONSTRATES BINDING TO KEY ADHESION RECEPTORS INVOLVED IN PATHOGENESIS OF SICKLE CELL DISEASE	Maria Lindgren Laursen	Received

757-P	GLUTATHIONE S TRANSFERASE GENE POLYMORPHISMS AND THE RISK OF CNS COMPLICATIONS OF SICKLE CELL DISEASE IN EGYPTIAN PATIENTS	Hend Ellithy Michelozzi	Received

760-P	INCREASED LEVELS OF CIRCULATING IMMATURE GRANULOCYTES IN SEPSIS HAVE A SIGNIFICANT IMPACT ON SURVIVAL: RESULTS OF THE FRENCH MULTICENTRIC SEPTIFLUX 2 STUDY	Estelle GUERIN Laursen	Received

761-P	USEFULNESS OF A THIRTY ONE-GENE PANEL BY NEXT-GENERATION SEQUENCING FOR THE MOLECULAR DIAGNOSTIC OF INHERITED BLEEDING COAGULATION DISORDERS	Jose Maria BASTIDA	Received

762-P	APPLICATION OF A MOLECULAR DIAGNOSTIC ALGORITHM FOR HEMOPHILIA A AND B USING NEXT-GENERATION SEQUENCING OF THE WHOLE F8, F9 AND VWF GENES.	Bastida Jose	Received

763-P	ASSAY DISCREPANCY IN MILD HAEMOPHILIA A PATIENTS WITH MUTATIONS IN FVIII A DOMAIN	Alenka Trampuš Bakija	Received

764-P	ARTHROPATHY IN PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE	Karin van Galen	Received

765-P	A COMPREHENSIVE NEXT GENERATION SEQUENCING TEST FOR THE DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET DISORDERS	Suthesh Sivapalaratnam Galen	Received

766-P	THE ROLE OF CD72 IN THE REGULATION OF B CELL ACTIVATION THROUGH CD40 IN PRIMARY IMMUNE THROMBOCYTOPENIA	Mingen Lyu	Received

768-P	QUALITATIVE AND QUANTITATIVE ANALYSIS OF INTRAHEPATIC BLOOD FLOW CHANGES IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)	Roland Schelker BASTIDA	Received

771-P	RECOMBINANT THROMBOMODULIN AMELIORATES HEMATOLOGICAL MALIGNANCY-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION MORE PROMPTLY THAN CONVENTIONAL THERAPY WITHOUT CAUSING SEVERE HEMORRHAGIC EVENTS	Naoki Kurita Galen	Received

772-P	EXTRACELLULAR HISTONES ENHANCE FACTOR XA MEDIATED PROTHROMBIN ACTIVATION WITHOUT PHOSPHOLIPID REQUIREMENT	Yasmina Sahraoui Galen	Received

773-P	PHORBOL 12-MYRISTATE-13-ACETATE INDUCES VON WILLEBRAND FACTOR PROPEPTIDE RELEASE FROM ENDOTHELIAL CELLS FROM 2 DISTINCT COMPARTMENTS	Ruben Bierings Galen	Received

774-P	NEWLY DIAGNOSED PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH ENHANCED TF PATHWAY ACTIVATION, THROMBIN GENERATION AND INCREASED CONCENTRATION OF PROCOAGULANT MICROPARTICLES	Despoina Fotiou BASTIDA	Received

775-P	ROLE OF ROTATIONAL THROMBELASTOMETRY (ROTEM®) IN RAPID ESTIMATION OF RIVAROXABAN DRUG LEVEL	Hun Chuah Galen	Received

778-P	INCIDENCE OF PERIPHERAL CIRCULATING CELLS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PHENOTYPE A FIRST EPISODE OF CEREBRAL SINUS VEIN THROMBOSIS: RESULTS FROM A PROSPECTIVE MULTICENTER STUDY	Mariasanta Napolitano	Received

779-P	REGULATION OF WEIBEL-PALADE BODY EXOCYTOSIS FROM ENDOTHELIAL CELLS BY SYNTAXIN-3 AND STXBP5 CONTAINING SNARE COMPLEXES.	Ruben Bierings	Received

780-P	COMPARISON OF QUALITY OF LIFE BETWEEN LONG-TERM SURVIVORS OF INDOLENT AND AGGRESSIVE LYMPHOMA: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY	Seok Jin Kim	Received

781-P	IMPACT OF IRON DEFICIENCY ON QUALITY OF LIFE AND WORK CAPACITY OF WOMEN	Lucilia Caramelo Kim	Received

782-P	IRON DEFICIENCY: UNDERSTANDING PERCEPTIONS OF SUFFERERS AND THE GENERAL PUBLIC	Lucilia Caramelo Kim	Received

784-P	THE RELATIVE BURDEN OF AL AMYLOIDOSIS ON HEALTH-RELATED QUALITY OF LIFE	Kristen L. McCausland	Received

785-P	OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA IN A LARGE COHORT INSIDE A PHASE 1 CLINIC DEPARTMENT.	Jean-Marie Michot McCausland	Received

787-P	HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN LONGITUDINAL STUDIES INCLUDING MULTIPLE MYELOMA PATIENTS: A CRITICAL REVIEW OF INTERPRETING CHANGES OF SCORES OBTAINED BY EORTC QLQ-C30	Lene Kongsgaard Nielsen	Received

2239-LB		Giovanni Cazzaniga	Received

2242-LB		David Britton	Received

2244-LB		Claudio Cerchione	Received

2249-LB		Jeffrey Johnston	Received

2251-LB		Rainer Hubmann	Received

2253-LB		K. Byrgazov	Received

2255-LB		Giovanni Caocci	Received

2258-LB		Claudio Cerchione	Received

2264-LB		Monika Klimkowska	Received

2266-LB		Yohei Kanamori	Received

2268-LB		S. Ekwattanakit	Received

21st Congress of EHA

June 9th - June 12th 2016 Copenhagen

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 10/06/2016 TO 10/06/2016

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.21EHA.2016



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access